MAPT and Cognitive impairment: TwX treatment (20 mg/kg/d, from 4.5 to 12 months) significantly ameliorated cognitive deficit, amyloid-β, tau and α-synuclein pathology, neuronal loss and neurovascular dysfunction, and this was accompanied by the attenuation of both oxidative stress (4-HNE, 8-OHdG) and inflammatory markers (NACHT, LRP and PYD domains-containing protein 3 (NLRP3), caspase-1, IL-1β, Iba-1 and TNF-α) [110].